SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors have established application in the treatment of type 2 diabetes in COPD (NICE, 2013) and potential application as an insulin adjunct in the treatment of the insulin‐deficient diabetes seen in CF (Argento and Nakamura, 2016).